Healthline Media Inc. announced that the company’s Healthline property, with a total of 67.3 million unique visitors in August 2018, is one of the top 50 digital media properties for the first time according to media measurement firm, comScore.
If you are a clinical researcher or scientist, you are well-aware of the inefficiencies of current search processes that require hours of time wading through data to find hidden nuggets of valuable info.
Sanofi will change the organizational structure of two Global Business Units to provide greater focus on operations in mature markets and across emerging markets.
Boston Scientific announced a definitive agreement to acquire Augmenix Inc., a privately held company that has developed and commercialized the SpaceOAR System, a therapy used to reduce common and debilitating side effects that men may experience after receiving prostate cancer radiotherapy.
Novartis agreed to sell selected portions of its Sandoz U.S. portfolio, specifically the Sandoz U.S. dermatology business and generic U.S. oral solids portfolio, to Aurobindo Pharma USA for $900 million in cash plus $100 million in potential earn-outs.
Checkmate Pharmaceuticals announced a clinical trial collaboration and supply agreement with the alliance between Merck KGaA and Pfizer Inc. to evaluate the TLR9 agonist CMP-001 in combination with the human anti-PD-L1 antibodyavelumab.
Sanofi reached a civil settlement with the U.S. Securities and Exchange Commission fully resolving the SEC’s investigation into possible violations of the U.S. Foreign Corrupt Practices Act.
Americans suffering from a “vacation deficit” are nearly two times as likely to show signs of moderately severe to severe depression compared to the national average, according to the 10th annual Allianz Global Assistance Vacation Confidence Index.
bluebird bio Inc. and Gritstone Oncology Inc. announced a collaboration to research, develop and commercialize products for the treatment of cancer using cell therapy.
Sierra Oncology Inc. announced that the clinical-stage drug-development company acquired the drug candidate momelotinib from Gilead Sciences.
